Jemperli plus chemotherapy demonstrated superior overall survival compared to Keytruda in advanced NSCLC, with a median OS of ...

Though GSK has put considerable effort into developing pharmacological treatments for gynecological cancers—including Zejula, ...

A curated review of what has happened in endometrial cancer research in 2024, including expert commentary, FDA approvals, healthcare disparities, AI, immunotherapies, and more.

MI Cancer Seek has received approval from the FDA as a companion diagnostic test to identify those who may benefit from ...

Top-line Phase 2b data anticipated for ANB032, our BTLA agonist, in atopic dermatitis (AD) in December 2024 Top-line Phase 2b data anticipated for rosnilimab, our PD-1 agonist, in rheumatoid arthritis ...

For the most current information about the device indications for the therapeutic products in this group, go to: ...

Mark A. Lewis, MD, discusses dostarlimab-gxly and how experts can best counsel patients with locally advanced mismatch repair ...

GSK's Q3 earnings beat estimates but sales miss the same. The company also lowers its outlook for vaccine sales for the rest of the year due to weak U.S. demand.